Zobrazeno 1 - 10 of 14 pro vyhledávání: '"Aradhana Awasthi Tiwari"'
1
Polatuzumab Vedotin, an Antibody-Drug Conjugate Targeting CD79b, Is a Highly Active Agent Against Burkitt Lymphoma and Primary Mediastinal B-Cell Lymphoma
Autor: Lauren Harrison, Mitchell S. Cairo, Jessica Hochberg, Dina Edani, Aradhana Awasthi Tiwari, Erin Morris, Anthony N. Audino, Matthew J. Barth, Christian Klein, Janet Ayello, Stanton Goldman
Publikováno v: Blood. 134:3963-3963
Introduction Mature B-cell lymphoma (MBL) accounts for approximately 60% of all non-Hodgkin lymphoma (NHL) in children and adolescents (Cairo et al, Blood, 2007). MBL in children and adolescents is comprised of approximately 75-80% Burkitt lymphoma (
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::96d9c818477822922cb58573937b27ac
https://doi.org/10.1182/blood-2019-128580
Zobrazit plný text záznamu
2
Abstract 1537: Polatuzumab Vedotin alone or in-combination with anti-CD20 antibody significantly enhanced overall survival in xenografted NSG mice against rituximab sensitive and resistant Burkitt Lymphoma (BL) and Primary Mediastinal B-cell Lymphoma (PMBL)
Autor: Janet Ayello, Dina Edani, Christian Klein, Aradhana Awasthi Tiwari, Mitchell S. Cairo
Publikováno v: Cancer Research. 79:1537-1537
Background: Patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma (B-NHL) have an unfavorable prognosis with few treatment options (Goldman/Cairo et al. Leukemia, 2013). It is therefore critical to investigate and to develop targeted trans
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5af61ca7ba417c8e301cd166cec27f85
https://doi.org/10.1158/1538-7445.am2019-1537
Zobrazit plný text záznamu
3
Abstract 2565: EBV peptide-derived vaccine significantly enhanced in vitro cytotoxicity against EBV-positive B-cell lymphoma (EBV-BL) treatment using TMV-based delivery system
Autor: Christeen Azmy, Dina Edani, Aaron Newman, Mitchell S. Cairo, Aradhana Awasthi Tiwari, Alison A. McCormick, Janet Ayello, Christian Klein
Publikováno v: Cancer Research. 78:2565-2565
Background: EBV latent proteins (LMP-1/2) increase the chemoresistance in Burkitt Lymphoma (BL) cells by constitutively activating the CD40 receptor. It has also been demonstrated that B- cell lymphoma resistant to rituximab is a result of LMP-1 indu
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::670fe74805f3d6458b32c2634fbeba24
https://doi.org/10.1158/1538-7445.am2018-2565
Zobrazit plný text záznamu
4
Abstract 1788: Enhanced in vitro/in vivo cytotoxicity against Burkitt lymphoma/primary mediastinal large B cell lymphoma by polatuzumab vedotin (hu- anti-CD79b-vc-MMAE, PV) alone or in combination with obinutuzumab
Autor: Janet Ayello, Dina Edani, Christeen Azmy, Mitchell S. Cairo, Christian Klein, Aradhana Awasthi Tiwari
Publikováno v: Cancer Research. 78:1788-1788
Background: Mature B-NHL, including Burkitt lymphoma (BL) and primary mediastinal large B cell lymphoma (PMBL) express CD20+/CD79b+ and have an excellent prognosis, however, subset of patients relapse secondary to chemoimmunotherapy resistant disease
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5691fc8976d01924c1bfcc338bac6bef
https://doi.org/10.1158/1538-7445.am2018-1788
Zobrazit plný text záznamu
5
Abstract 2656: Polatuzumab vedotin significantly enhances in vitro cell death and overall survival against CD79b+ Burkitt lymphoma (BL)/primary mediastinal large B-cell lymphoma (PMBL) NSG xenograft mice
Autor: Janet Ayello, Christeen Azmy, Aradhana Awasthi Tiwari, Mitchell S. Cairo, Carmella van de Ven
Publikováno v: Cancer Research. 77:2656-2656
Background: Mature B-NHL, including Burkitt lymphoma and primary mediastinal large B cell lymphoma express CD79b+ and have an excellent prognosis with chemo-immunotherapy (Cairo et al Blood, 2007, Gerrard/Cairo et al. Blood, 2013). However, a subset
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3dd811564b8104de4173ea46b255958f
https://doi.org/10.1158/1538-7445.am2017-2656
Zobrazit plný text záznamu
7
Abstract 579: Antibody drug conjugates (anti-CD79b-vc-MMAE, Polatuzumab Vedotin) exhibit enhanced cell death targeted to CD79b+ Burkitt lymphoma (BL) and primary mediastinal large B-cell lymphoma (PMBL)
Autor: Carmella van de Ven, Mitchell S. Cairo, Matthew J. Barth, Aradhana Awasthi Tiwari, Janet Ayello, Lisa Kurien
Publikováno v: Cancer Research. 76:579-579
Background: Mature B-NHL, including Burkitt lymphoma (BL) and primary mediastinal large B cell lymphoma (PMBL) express CD79b+ and have an excellent prognosis with chemo-immunotherapy (Cairo et al Blood, 2007,Goldman/Cairo et al. Leukemia, 2013, Gerra
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::9f63ade0bb54ca2ccb07ee79751e5454
https://doi.org/10.1158/1538-7445.am2016-579
Zobrazit plný text záznamu
9
Abstract 2479: Obinutuzumab compared to Rituximab significantly enhances cell death, antibody dependent cytotoxicity (ADCC) and improves overall survival against CD20+ rituximab-sensitive/-resistant Burkitt Lymphoma (BL) and precursor Lymphoblastic L
Autor: Mona Elmacken, Carmella vandeVen, Mitchell S. Cairo, Christian Klein, Matthew J. Barth, Janet Ayello, Aradhana Awasthi Tiwari
Publikováno v: Cancer Research. 75:2479-2479
Background: CD20, expressed on normal and malignant B-cells, has proven to be a useful target for immunotherapeutic approaches in hematological malignancies. (Dalle, S et al. Mol. Can. Ther., 2011) Patients who relapse with CD20+ BL/ B-ALL have a dis
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::8b80f627290564c520b80c15187a52ff
https://doi.org/10.1158/1538-7445.am2015-2479
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje